Viridian Therapeutics Inc (NASDAQ: VRDN) on Friday, plunged -3.11% from the previous trading day, before settling in for the closing price of $17.05. Within the past 52 weeks, VRDN’s price has moved between $9.90 and $27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 31.28% annually for the last half of the decade. The company achieved an average annual earnings per share of -7.33%. With a float of $73.61 million, this company’s outstanding shares have now reached $81.59 million.
In an organization with 143 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -1858.28%, operating margin of -111591.06%, and the pretax margin is -102092.38%.
Viridian Therapeutics Inc (VRDN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viridian Therapeutics Inc is 9.78%, while institutional ownership is 103.45%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -7.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.32% during the next five years compared to 31.28% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Viridian Therapeutics Inc (VRDN) is currently performing well based on its current performance indicators. A quick ratio of 19.49 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4493.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.05, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -3.80 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.64 million. That was inferior than the volume of 0.92 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 64.64%.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 86.76%, which indicates a significant increase from 72.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.85 in the past 14 days, which was higher than the 0.82 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.67, while its 200-day Moving Average is $17.45. However, in the short run, Viridian Therapeutics Inc’s stock first resistance to watch stands at $17.08. Second resistance stands at $17.64. The third major resistance level sits at $17.95. If the price goes on to break the first support level at $16.21, it is likely to go to the next support level at $15.90. Assuming the price breaks the second support level, the third support level stands at $15.34.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
Market capitalization of the company is 1.35 billion based on 81,592K outstanding shares. Right now, sales total 300 K and income totals -269,950 K. The company made 70 K in profit during its latest quarter, and -86,910 K in sales during its previous quarter.
